Results 61 to 70 of about 8,134 (194)

A Case of Worsened Refractory Ascites due to Prednisolone Administration for Stricture Prevention after Endoscopic Submucosal Dissection for Extensive Early Esophageal Cancer: Case Report and Literature Review

DEN Open, Volume 6, Issue 1, April 2026.
ABSTRACT Endoscopic submucosal dissection (ESD) is widely used for early esophageal cancer, even in patients with liver cirrhosis (LC). Corticosteroids, administered orally or by local injection, are often used to prevent post‐ESD esophageal stricture. However, their safety in patients with decompensated LC and refractory ascites remains unclear. A man
Yuki Tamura, Masanori Sekiguchi, Kaho Honda, Yu Maruyama, Kenta Ito, Makiko Inoue, Mitsuhiko Shibasaki, Daichi Takizawa, Hirotaka Arai, Toshio Uraoka   +9 more
wiley   +1 more source

European ADPKD Forum multidisciplinary position statement on autosomal dominant polycystic kidney disease care [PDF]

, 2017
Autosomal dominant polycystic kidney disease (ADPKD) is a chronic, progressive condition characterised by the development and growth of cysts in the kidneys and other organs and by additional systemic manifestations.
Alastair Kent, Albert C M Ong, Brenda de Coninck, Denis Clément, Dorien Peters, Elena Levtchenko, Hendrik Van Poppel, Joost P H Drenth, José Luis Górriz, Klemens Budde, Lorenzo E Derchi, Marianna Eleftheroudi, null null, null null, null null, Olivier Devuyst, Raymond Vanholder, Richard Sandford, Ron T Gansevoort, Tess Harris, Tevfik Ecder, Vicente E Torres, Yves Pirson   +22 more
core   +6 more sources

Long-Term Effects of High-Dose Tolvaptan for Autosomal Dominant Polycystic Kidney Disease Patients

Case Reports in Nephrology and Dialysis, 2020
Tolvaptan, a vasopressin V2 receptor antagonist, was initially approved in Japan for treatment of autosomal dominant polycystic kidney disease (ADPKD).
Shinya Nakatani, Eiji Ishimura, Yuri Machiba, Kenta Fujimoto, Hideki Uedono, Akihiro Tsuda, Katsuhito Mori, Masanori Emoto, Masaaki Inaba   +8 more
doaj   +1 more source

Rare but relevant: MDMA and hyponatraemia

Addiction, Volume 121, Issue 3, Page 713-718, March 2026.
Abstract Conventionally used for its stimulant, empathogenic and entactogenic effects, 3,4‐methylenedioxymethamphetamine (MDMA, ecstasy) is one of the most commonly used psychoactive drugs, specifically among young adults and in nightlife and recreational party contexts.
Maria Rita Garcia, Nelson G. M. Gomes, Diana Dias‐da‐Silva   +2 more
wiley   +1 more source

Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3:4

Kidney International Reports, 2017
In the randomized placebo-controlled Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes (TEMPO) 3:4 trial, tolvaptan slowed kidney growth and renal function decline in subjects with autosomal ...
Olivier Devuyst, Arlene B. Chapman, Susan E. Shoaf, Frank S. Czerwiec, Jaime D. Blais   +4 more
doaj   +1 more source

Hyponatremia revisited: Translating physiology to practice [PDF]

, 2008
The complexity of hyponatremia as a clinical problem is likely caused by the opposite scenarios that accompany this electrolyte disorder regarding pathophysiology (depletional versus dilutional hyponatremia, high versus low vasopressin levels) and ...
Adrogue HJ, Anderson RJ, Aw TC, Bankir L, Beukhof CM, Bourque CW, Burbach JP, Carlotti AP, Chou CL, Chow KM, Chung HM, Decaux G, Decaux G, Decaux G, Decaux G, Detmers FJ, Diederich S, Dzau VJ, Ellison DH, Ewout J. Hoorn, Friedman E, Gagnon RF, Ghorbel MT, Goldberg A, Halperin ML, Hamburger S, Hoorn EJ, Hoorn EJ, Hoorn EJ, Hoorn EJ, Hsu YJ, Knochel JP, Kurotani R, Liamis G, Lohr JW, Londono MC, Maesaka JK, Maesaka JK, McGee S, McKinley MJ, Moritz ML, Musch W, Nielsen S, Noakes TD, Oliet SH, Papanicolaou DA, Patel GP, Porcel A, Reynolds RM, Robert Zietse, Robertson GL, Schrier RW, Schrier RW, Schrier RW, Shafiee MA, Siegel AJ, Smith JC, Sonnenblick M, Thaler SM, Turchin A, Umenishi F, Verbalis JG, Warner MH   +62 more
core   +2 more sources

Toward the harmonization of bioequivalence guidelines in Europe: Commentary on the state of the art and future priorities under ICH M13A for immediate‐release oral forms

British Journal of Clinical Pharmacology, EarlyView.
Domenico Nocera, Giusi Forastiero, Andrea Logreco, Alessia Proietti, Antonio Galluccio, Carlotta Lunghi, Elisabetta Poluzzi, Fabrizio De Ponti   +7 more
wiley   +1 more source

Tolvaptan [PDF]

British Journal of Clinical Pharmacology, 2011
Eline A, Dubois, Robert, Rissmann, Adam F, Cohen   +2 more
openaire   +3 more sources

Idiosyncratic hepatic toxicity in autosomal dominant polycystic kidney disease (ADPKD) patient in combined treatment with tolvaptan and amoxicillin/clavulanic acid: a case report

BMC Nephrology, 2019
Background Autosomal dominant polycystic kidney disease (ADPKD) is a hereditary disease characterized by the presence of renal cysts. Over time the expanding cysts lead to progressive renal failure.
Angela Maria Pellegrino, Luigi Annicchiarico Petruzzelli, Eleonora Riccio, Antonio Pisani   +3 more
doaj   +1 more source

A Case of Paroxysmal Sympathetic Hyperactivity due to Cardiogenic Shock

Acute Medicine &Surgery, Volume 13, Issue 1, January/December 2026.
Paroxysmal sympathetic hyperactivity (PSH) following cardiogenic shock without structural brain injury. A patient with cardiogenic shock requiring mechanical circulatory support developed recurrent episodes of hyperthermia, tachycardia, tachypnea, diaphoresis, and hypertonia during recovery.
Takahito Katsuyama, Chiaki Toida, Yasuaki Maeda, Masao Hattori, Akiko Kameyama, Hiroshi Kamijo, Hiroshi Miyama, Yuichiro Kashima, Hiroshi Imamura   +8 more
wiley   +1 more source